This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.
Extensive Stage-small Cell Lung Cancer
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
-
University of Alabama -Birmingham, Birmingham, Alabama, United States, 35233
David Geffen School of Medicine, Los Angeles, California, United States, 90095
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States, 92663
Mayo Clinic-Jacksonville, Jacksonville, Florida, United States, 32224
Adventhealth Orlando, Orlando, Florida, United States, 32804
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States, 60611
Henry Ford Hospital, Detroit, Michigan, United States, 48202
Regents of the University of Minnesota, Minneapolis, Minnesota, United States, 55455
Mayo Clinic, Rochester, Minnesota, United States, 55905
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States, 03766
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Daiichi Sankyo,
Global Clinical Leader, STUDY_DIRECTOR, Daiichi Sankyo
2026-12-30